Skip to content
Screener

EPS (Diluted) at other companies

Bausch Health Companies logo
Bausch Health CompaniesBHC
-$3.82-2,287%
Ardelyx logo
ArdelyxARDX
-$0.07+12.5%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$0.44-30.2%
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
-$1.06-783%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
-$0.69-199%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$1.91+2,287%

Other financials

Income statement

See full
Revenue$113.0M+32.6%
Operating income$79.3M+75.0%
Net income$51.3M+117%

Balance sheet

See full
Cash & equivalents$79.1M-14.8%
Total debt$11.9M-94.4%
Total equity-$161.8M+47.5%
Total assets$285.1M-16.9%

Cash flow

See full
Operating cash flow$58.3M
CapEx-
Free cash flow$74.6M+390%

Valuation

See full
Market cap$713.84M+427%
Enterprise value$646.58M+152%
P/E5.5×
P/S1.8×+1.4×

Profitability

See full
Gross margin99.2%
Operating margin60.1%+36.4pp
Net margin33.4%+31.1pp
FCF margin24.7%-11.1pp

Returns & leverage

See full
Return on equity29.7%-138pp
Debt / equity-0.5×
Current ratio6.1×+5.2×

Where this comes from

Reported directly by Ironwood Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The source filing: Ironwood Pharmaceuticals’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:07 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001104659-26-091987
Line itemThree Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Other income (expense), net(5,576)(7,499)(12,977)(14,663)
Income before income taxes73,73137,822138,9031,550
Income tax expense(22,440)(14,223)(46,839)(15,337)
Net income (loss)$51,291$23,599$92,064$(13,787)
Net income (loss) per share — basic$0.31$0.15$0.56$(0.09)
Net income (loss) per share — diluted$0.31$0.14$0.55$(0.09)
Weighted average shares used in computing net income (loss) per share — basic164,405161,723163,930161,350
Weighted average shares used in computing net income (loss) per share — diluted167,179176,837167,036161,350

Item 1. Condensed Consolidated Financial Statements (unaudited)

FAQ

What is Ironwood Pharmaceuticals's EPS (diluted)?
Ironwood Pharmaceuticals (IRWD) reported EPS (diluted) of $0.31 in Q2 2026.
How has Ironwood Pharmaceuticals's EPS (diluted) changed year-over-year?
Ironwood Pharmaceuticals's EPS (diluted) increased by 121.4% year-over-year, from $0.14 to $0.31.
What is the long-term trend for Ironwood Pharmaceuticals's EPS (diluted)?
Over 4 years (2021 to 2025), Ironwood Pharmaceuticals's EPS (diluted) has grown at a -55.2% compound annual growth rate (CAGR), from $3.23 to $0.13.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.

Ask your AI about Ironwood Pharmaceuticals's eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude